<DOC>
	<DOCNO>NCT01314313</DOCNO>
	<brief_summary>The purpose trial determine safety effectiveness Edwards SAPIEN XT Edwards SAPIEN 3 transcatheter heart valve delivery system intend use patient symptomatic , calcific , severe aortic stenosis .</brief_summary>
	<brief_title>The PARTNER II Trial : Placement AoRTic TraNscathetER Valves</brief_title>
	<detailed_description>A prospective multi-center trial patient undergoing aortic valve replacement severe aortic stenosis . Patient cohort include follow group base operative risk surgical aortic valve replacement : inoperable , high surgical risk ( STS ≥ 8 % ) , intermediate risk ( STS = 4-8 % ) . The Edwards SAPIEN XT transcatheter heart valve ( THV ) system study patient deem inoperable intermediate risk . A subset inoperable patient randomize receive transcatheter aortic valve replacement ( TAVR ) either SAPIEN XT THV SAPIEN THV . The SAPIEN XT study intermediate risk patient randomize receive TAVR SAPIEN XT surgical AVR . The Edwards SAPIEN 3 THV study non-randomized fashion patient three risk group . Data collect patient five year follow valve replacement procedure .</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>Inclusion Criteria All Candidates study ( Cohorts A , B S3 ) must meet following criterion : 1 . Patient senile degenerative aortic valve stenosis echocardiographically derive criterion : mean gradient &gt; 40 mmHg jet velocity great 4.0 m/s initial aortic valve area ( AVA ) ≤0.8 cm2 indexed EOA &lt; 0.5 cm2/m2 Qualifying echo must within 60 day date procedure . 2 . Patient symptomatic his/her aortic valve stenosis , demonstrate NYHA Functional Class II great . 3 . The heart team agree ( verified case review process ) valve implantation likely benefit patient . 4 . The study patient study patient 's legal representative inform nature study , agree provision provide write informed consent approve Institutional Review Board ( IRB ) respective clinical site . 5 . The study patient agree comply required postprocedure followup visit include annual visit 5 year analysis close date visit , conduct phone followup . Once eligibility accordance criterion establish , patient assess operability ( inoperable , high risk , intermediate risk ) . All candidate must meet criterion order stratify Cohort A , Cohort B S3 . Additional Eligibility Criteria Specific Cohort A : 1 . STS ≥ 4 2 . Heart team ( include examine cardiac surgeon ) agree eligibility include assessment TAVR AVR appropriate 3 . Heart team agree ( priori ) treatment strategy concomitant coronary disease ( present ) 4 . Study patient agrees undergo surgical aortic valve replacement ( AVR ) randomize control treatment . Additional Eligibility Criteria Specific Cohort B 1 . The heart team agree medical factor preclude operation , base conclusion probability death serious , irreversible morbidity exceed probability meaningful improvement . Specifically , probability death serious , irreversible morbidity ≥ 50 % . 2 . The heart team agree patient likely benefit valve replacement . Additional Eligibility Criteria Specific PIIS3 High Risk Cohort/ NR7 1 . STS &gt; 8 2 . For inoperable patient : Same # 1 additional eligibility criterion specific Cohort B 3 . Aortic valve annulus area range ( 273mm2680 mm2 ) per 3D imaging ( echo , CT MRI ) . Additional Eligibility Criteria Specific PIIS3 Intermediate Risk Cohort/ NR8 1 . Assessment Intermediate surgical risk define STS 48 % Heart Team assessment intermediate risk factor . 2 . Aortic valve annulus area range ( 273 mm2680 mm2 ) per 3D imaging ( echo , CT , MRI ) . 3 . Heart team agree ( priori ) treatment strategy concomitant coronary disease ( present ) . Exclusion Criteria Exclusion Criteria Cohort A , Cohort B S3 Cohorts ( include NR7 NR8 ) : 1 . Evidence acute myocardial infarction ≤ 1 month ( 30 day ) intend treatment [ define : Q wave MI , nonQ wave MI total CK elevation CKMB ≥ twice normal presence MB elevation and/or troponin level elevation ( WHO definition ) ] . 2 . Aortic valve congenital unicuspid congenital bicuspid valve , noncalcified . 3 . Mixed aortic valve disease ( aortic stenosis aortic regurgitation predominant aortic regurgitation &gt; 3+ ) . 4 . Preexisting mechanical bioprosthetic valve position ( except NR3 ) . 5 . Any therapeutic invasive cardiac procedure result permanent implant perform within 30 day index procedure ( unless part plan strategy treatment concomitant coronary artery disease ) . Implantation permanent pacemaker ICD ( S3 Cohort ) exclude . 6 . Any patient balloon valvuloplasty ( BAV ) within 30 day procedure ( unless BAV bridge procedure qualify ECHO ) . 7 . Patient plan concomitant surgical transcatheter ablation Atrial Fibrillation . 8 . Leukopenia ( WBC &lt; 3000 cell/mL ) , acute anemia ( Hgb &lt; 9 g/dL ) , Thrombocytopenia ( Pit &lt; 50,000 cell/mL ) . 9 . Hypertrophic cardiomyopathy without obstruction ( HOCM ) . 10 . Severe ventricular dysfunction LVEF &lt; 20 % . 11 . Echocardiographic evidence intracardiac mass , thrombus , vegetation . 12 . Active upper GI bleeding within 3 month ( 90 day ) prior procedure . 13 . A known contraindication hypersensitivity anticoagulation regimen , inability anticoagulated study procedure . 14 . Clinically ( neurologist ) neuroimaging confirm stroke transient ischemic attack ( TIA ) within 6 month ( 180 day ) procedure . 15 . Renal insufficiency ( creatinine &gt; 3.0 mg/dL ) and/or renal replacement therapy time screen . 16 . Estimated life expectancy &lt; 24 month ( 730 day ) due carcinoma , chronic liver disease , chronic renal disease chronic end stage pulmonary disease . 17 . Expectation patient improve despite treatment aortic stenosis . 18 . Currently participate investigational drug another device study . Note : Trials require extend followup product investigational , since become commercially available , consider investigational trial . 19 . It known patient currently enrol The PARTNER I Trial . 20 . Active bacterial endocarditis within 6 month ( 180 day ) procedure . Exclusion Criteria Specific Cohort A : 1 . Heart team assessment inoperability ( include examine cardiac surgeon ) . 2 . Complex coronary artery disease : Unprotected leave main coronary artery Syntax score &gt; 32 ( absence prior revascularization ) 3 . Native aortic annulus size &lt; 18 mm &gt; 27 mm measure echocardiogram . 4 . Patient refuse aortic valve replacement surgery . Exclusion Criteria Specific Cohort B S3 Cohorts ( include NR7 NR8 ) : 1 . Heart team assessment inoperability ( include examine cardiac surgeon ) . PIIS3 intermediate risk cohort NR8 . 2 . Untreated clinically significant coronary artery disease require revascularization . Cohort B , PIIS3 high risk cohort NR7 . 3 . Complex coronary artery disease ( S3i ) NR8 ) : 1 . Unprotected leave main coronary artery 2 . Syntax score &gt; 32 ( absence prior revascularization ) 4 . Hemodynamic respiratory instability require inotropic support , mechanical ventilation mechanical heart assistance within 30 day screen evaluation . 5 . Need emergency surgery reason . 6 . Native aortic annulus size &lt; 18 mm &gt; 25 mm Cohort B &lt; 16mm &gt; 28mm S3 Cohort ( include NR7 , NR8 CAP ) , measure echocardiogram . 7 . Significant aortic disease , include mark tortuosity ( hyperacute bend ) , aortic arch atheroma [ especially thick ( &gt; 5 mm ) , protrude ulcerated ] narrowing ( especially calcification surface irregularity ) abdominal thoracic aorta , severe `` unfolding '' tortuosity thoracic aorta ( Transfemoral ) . 8 . Iliofemoral vessel characteristic would preclude safe placement 22F 24F Cohort B 14F 16F S3 Cohorts ( include NR7/NR8 ) introducer sheath severe obstructive calcification . Severe tortuosity minimum average vessel size le 7 mm ( 5.5 mm S3 Cohorts NR7/NR ) ( Transfemoral ) . Specific Criteria Registry 1 ( NR1 ) Registry 4 ( NR4 ) Inclusion : Same criterion Cohort B Including nonfemoral access . Exclusion : Same criterion Cohort B except exclusionary criterion # 15 excludes patient renal insufficiency ( creatinine &gt; 3.0 mg/dL ) . Specific Criteria Registry 2 ( NR2 ) Inclusion : Same criterion Cohort B Including nonfemoral access Exclusion : Same criterion Cohort B , except exclusion 22 modify NR2 follow : • Iliofemoral vessel characteristic would preclude safe placement 22F 24F introducer sheath severe obstructive calcification , severe tortuosity minimum average vessel size le 6 mm exclusionary criterion # 15 excludes patient renal insufficiency ( creatinine &gt; 3.0 mg/dL ) . Specific Criteria Registry 3 ( NR3 ) Inclusion : 1 . Stenosed insufficient surgically implant bioprosthetic valve aortic position . 2 . NYHA class &gt; II . 3 . Heart team consensus risk surgical mortality major morbidity ≥ 50 % . Exclusion : 1 . Bioprosthetic valve label external diameter &lt; 21mm . 2 . Surgical transcatheter valve another position side heart ( mitral tricuspid ring exclusion ) . 3 . Hemodynamic instability define require inotropic , pressor , mechanical support . 4 . Infectious endocarditis within 6 month . 5 . Bacteremia within 1 month . 6 . Intracardiac thrombus vegetation . 7 . Acute myocardial infarction ≤ 1 month ( 30 day ) intend treatment [ define : Q wave MI , nonQ wave MI total CK elevation ≥ twice normal presence MB elevation and/or troponin level elevation ( WHO definition ) ] . 8 . Percutaneous coronary intervention implantation permanent pacemaker within 7 day index procedure . 9 . Leukopenia ( WBC &lt; 3000 cell/mL ) , acute anemia ( Hgb &lt; 9 g/dL ) , thrombocytopenia ( Plt &lt; 50,000 cell/mL ) . 10 . Hypertrophic cardiomyopathy obstruction ( HOCM ) . 11 . Severe ventricular dysfunction LVEF &lt; 20 % . 12 . Active upper GI bleeding within 3 month ( 90 day ) prior procedure require transfusion . 13 . Inability anticoagulated study procedure . 14 . Stroke transient ischemic attack within 6 month ( 180 day ) . 15 . Insufficiency ( creatinine &gt; 3.0 mg/dL ) . 16 . Estimated life expectancy &lt; 24 month . 17 . Participating investigational drug another device study . Note : Trials require extend followup product investigational , since become commercially available , consider investigational trial . 18 . The patient require emergency surgery reason . 19 . Xenograft THV another position . 20 . Index valve moderate severe paravalvular regurgitation . 21 . Index valve unstable rocking . 22 . Extensive , severe nonrevascularized coronary disease . 23 . Increased risk coronary obstruction prosthetic leaflet ( nonstented internally stented valve might extend coronary ostium ) . 24 . Increased risk embolization ( nonstented noncalcified valve ) . Specific Criteria Registry 5 ( NR5 ) Registry 6 ( NR6 ) Inclusion : Same criterion Cohort B include nonfemoral access Exclusion : Same criterion Cohort B except `` Native aortic annulus size &lt; 18mm &gt; 27mm measure echocardiogram exclusionary criterion # 15 excludes patient renal insufficiency ( creatinine &gt; 3.0 mg/dL ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>SAPIEN XT</keyword>
	<keyword>SAPIEN 3</keyword>
	<keyword>Transfemoral</keyword>
	<keyword>Transapical</keyword>
	<keyword>Transaortic</keyword>
	<keyword>NovaFlex</keyword>
	<keyword>TAVI</keyword>
	<keyword>Aortic Stenosis</keyword>
	<keyword>THV</keyword>
	<keyword>Aortic Valve</keyword>
	<keyword>Transcatheter Heart Valve</keyword>
	<keyword>tAVR</keyword>
</DOC>